Furthermore, the combination treatment of miR-34a and doxorubicin can significantly downregulate the expression of Snail by inhibiting the Notch/NF-κB and RAS/RAF/MEK/ERK pathways, thereby preventing doxorubicin-resistant breast cancer progression (248). The gene discussed is SNAI1; the disease is breast cancer.